Actemra: Heart Failure or Pancreatitis
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Actemra (tocilizumab) is approved by the FDA for the treatment of several different medical conditions:
- Moderately to severely active rheumatoid arthritis in adult patients who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs);
- Giant Cell Arteritis (GCA) in adult patients;
- Polyarticular Juvenile Idiopathic Arthritis (PJIA) in patients 2 years of age and older; and,
- Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older.
These medical conditions may have been caused by the use of Actemra:
- Heart Failure
- Heart Attacks / Myocardial Infarction (MI)
- Strokes (CVA)
- Interstitial Lung Disease (ILD)
The responsible drug company is Genentech, Inc.
We are currently investigating cases of these serious side effects in patients who used Actemra as possible drug injury lawsuits against this drug company — and not your doctor.
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About This Drug
An insightful article by reported Charles Piller, “Failure to warn: Hundreds died while taking an arthritis drug, but nobody alerted patients”, published June 5, 2017 online by STAT, put the spotlight on some serious but little-known side effects associated with this medicine from Genentech, Inc.
To read more of this article, click below:
… STAT analyzed more than 500,000 side-effect reports on rheumatoid arthritis drugs, and found clear evidence that the risks of heart attacks, strokes, heart failure, and other conditions were as high or higher for Actemra patients than for patients taking some competing drugs.
Most of those medications warn about these risks on their labels. Actemra does not.
Consumers are barraged every day with drug ads accompanied by numbing lists of side effects, but STAT’s investigation shows that the risks to patients might be greater than they are led to believe. The Food and Drug Administration has received reports on 1,128 people who died after taking Actemra, and has reviewed its safety several times since it was approved. But the agency doesn’t have sophisticated tools to determine whether the drug was a culprit or a bystander in those deaths….
Experts who examined the data at STAT’s request said the FDA should immediately consider warnings for heart failure and pancreatitis — an inflammation of the pancreas that in its acute form can kill up to 50 percent of patients. They said the evidence that Actemra might increase the risk of heart attacks, strokes, and interstitial lung disease, a sometimes-fatal scarring of lung tissue, is less convincing but warrants further review.
This focus on Actemra side effects and the lack of warnings about these adverse reactions shines the light on the apparent inadequate standards of post-marketing surveillance for drugs approved by the FDA.
We are interested in hearing about patients who were diagnosed with pancreatitis or some other serious side effect while using Actemra. You can do this by submitting a Quick Contact Form or by using the Email link found in the sidebar.[Read this article in full at original source]
All content by attorney Tom Lamb